License & Milestone Revenues was Cytokinetics’s largest product and service line in fiscal 2025, bringing in $79.30M of $88.00M (90%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Realization Of Revenue Participation Right Purchase Agreement | $87.00M | — | — | — | ||||
| License & Collaboration | — | — | — | — | ||||
| License & Milestone Revenues | $1.00M | $3.50M | $15.00M | $79.30M | ||||
| Reimbursements | — | — | — | — | ||||
| Research & Development Revenues | — | — | — | — | ||||
| Research & Development Milestone Grant And Other Revenues Net | — | — | — | — | ||||
| Collaboration Revenues | $6.60M | $4.03M | $6.87M | $8.70M | ||||
| Milestone Fees | — | — | — | — | ||||
| License | — | — | — | — | ||||
| Research & Development, Grant And Other Revenues, Net | — | — | — | — | ||||
| Co-Invest Option Payments | — | — | — | — | ||||
| Total | $94.60M | $7.53M | $21.87M | $88.00M |
Cytokinetics brought in $88.00M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 302.3% from $21.87M in fiscal 2024. License & Milestone Revenues was the largest at $79.30M (90.1%), ahead of Collaboration Revenues at $8.70M (9.9%).
Compared with fiscal 2024, License & Milestone Revenues grew 428.7% to $79.30M and Collaboration Revenues grew 26.6% to $8.70M.
Cytokinetics stopped reporting Realization Of Revenue Participation Right Purchase Agreement as a separate line after fiscal 2022, when it brought in $87.00M.
Bayer License Agreement was Cytokinetics’s largest revenue line in fiscal 2025, bringing in $64.30M of $79.30M (81%).
| Collaborative Arrangement and Arrangement Other than Collaborative | FY 2013 | FY 2014 | FY 2020 | FY 2022 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| Royalty Purchase Agreement | $87.00M | — | — | |||
| Collaborative Arrangement | — | — | — | |||
| Bayer License Agreement | — | $100.00K | $64.30M | |||
| Accounting For The License & Collaboration Agreements In China | — | $15.00M | $15.00M | |||
| Proportional Performance Model | — | — | — | |||
| Total | $87.00M | $15.10M | $79.30M |
Cytokinetics brought in $79.30M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That is less than the $88.00M it reports by product and service, so these revenue lines do not cover all of its revenue. Bayer License Agreement was the largest at $64.30M (81.1%), ahead of Accounting For The License & Collaboration Agreements In China at $15.00M (18.9%).
Compared with fiscal 2024, Bayer License Agreement grew 64,200.0% to $64.30M and Accounting For The License & Collaboration Agreements In China grew 0.0% to $15.00M.
Cytokinetics began breaking out Bayer License Agreement in fiscal 2024 and Accounting For The License & Collaboration Agreements In China in fiscal 2024. Cytokinetics stopped reporting Royalty Purchase Agreement as a separate revenue line after fiscal 2022, when it brought in $87.00M.
Cytokinetics (CYTK) reports its revenue by product and service and by collaborative arrangement and arrangement other than collaborative. In fiscal 2025, License & Milestone Revenues was its largest product and service line, bringing in $79.30M (90.1% of the total), followed by Collaboration Revenues at $8.70M (9.9%).
License & Milestone Revenues was Cytokinetics' largest product and service line in fiscal 2025, bringing in $79.30M, or 90.1% of the $88.00M total across its two product and service lines.
Bayer License Agreement was Cytokinetics' largest revenue line in fiscal 2025, bringing in $64.30M, or 81.1% of the $79.30M total across its two revenue lines.
License & Milestone Revenues grew faster than Collaboration Revenues in fiscal 2025, up 428.7% from $15.00M to $79.30M. Collaboration Revenues grew 26.6% to $8.70M.
Every figure comes from Cytokinetics' annual financial filings, as reported. Each line keeps the name Cytokinetics gives it, and years follow its fiscal calendar.
Cytokinetics' revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.